Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced a strategic cooperation agreement (SCA) with Toticell Limited for the distribution of the Group's products in Bangladesh.
More info..

Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, is collaborating with KL City FC Sdn Bhd (KLCFC), the manager of the KL City FC football club, on the deployment of the Group's genetic screening tests for peak athletic performance.
More info..

Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group recorded a revenue of RM1.64 million for the second quarter ended 31 December 2022 (2Q 2023). This amount is down from RM7.63 million in 2Q 2022, as the Group moved its focus from vaccines to biopharmaceuticals.
More info..

Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group has entered into a strategic collaboration with Kensana Health Canada and MAHSA University for the research and development (R&D) of phytopharmaceutical and biotechnology products that can lead to commercialisation.
More info..

Malaysian Genomics Resource Centre Bhd, a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a strategic collaboration agreement with Divine Genes Sdn Bhd to collaborate on business opportunities in relation to the improvement and international distribution of genetic tests for reproductive health.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce a strategic cooperation with SIRIM Berhad, to explore the commercialisation of joint research and development (R&D) projects in the medical and biotechnology fields.
More info..

Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today reported a revenue of RM3.81 million for the first quarter ended 30 September 2022 (1Q 2023) versus a revenue of RM9.32 million in 1Q 2022, as the Group refocuses on immunotherapy and cell therapies under the biopharmaceutical business and pushes for organic growth of its genetic screening business.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced the signing of a Strategic Collaboration Agreement (SCA) outlining partnerships to market and distribute the Group's Dtect(R) range of genetic screening services in the United Arab Emirates (UAE).
More info..

MGRC Therapeutics Sdn Bhd (MGRC-T), a wholly-owned subsidiary of Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, has entered into a cooperation agreement with the National Institutes of Health, Malaysia (NIH), providing a framework for collaboration between the two parties in medical research pertaining to genomics and biopharmaceuticals.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce today a series of collaborations to grow its customer base in Thailand as well as exploring opportunities for research and development (R&D) of new products and services.
More info..

Leading genomics and biopharmaceutical specialist Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155) is pleased to report that the Group has signed a letter of intent (LOI) with the Faculty of Science and Natural Resources, Universiti Malaysia Sabah (UMS) and Rinani Genotec Sdn Bhd (Genotec) to collaborate on research and development (R&D) in genetics, and regenerative and alternative medicines.
More info..

Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, reported revenue of RM6.33 million for the fourth quarter ended 30 June 2022 (4Q 2022) compared with the loss of RM0.07 million in the corresponding quarter of the previous financial year (4Q 2021) on higher contribution from the biopharmaceutical business and continued organic growth of the genetic testing business.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, today announced that the Group has signed a Memorandum of Understanding (MoU) to explore opportunities for the distribution of biopharmaceutical and genomics products and services with Ajlan & Bros Medical Company.
More info..

Malaysian Genomics Resource Centre Berhad's (Bursa: MGRC, 0155) wholly-owned subsidiary, MGRC Therapeutics Sdn. Bhd. signed a memorandum of understanding (MoU) with MAHSA Health Sdn Bhd to discuss the formation of a strategic partnership promoting practice-based education, research and knowledge exchange.
More info..

UCrest Berhad (ACE Market: 0005) and Malaysian Genomics Resources Centre Berhad, (ACE Market: 0155) announced today that they have signed a collaborative agreement to integrate genomic testing services into digital health platform, iMedic(TM), elevating healthcare services to the next level.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Company has appointed Dato' Seri Dr Chen Chaw Min as the Independent Non-Executive Chairman of the Board of Directors.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that it has entered into a strategic partnership with United Doctors Hospital (UDH) for collaboration in genomics and cell therapies.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is proposing to undertake a private placement of up to 10% of its total number of issued shares or up to 12.42 million new placement shares at an issue price to be determined for third-party investors that will be identified later.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that the Group's wholly-owned subsidiary, MGRC Therapeutics Sdn Bhd (MGRCT), is collaborating with Rinani Genotec Sdn Bhd (Genotec) to offer sports-based genetic tests.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, announced today that the Group is acquiring a 51% stake in Aquahealth Sdn Bhd, a kidney dialysis operator, from Rinani Renal Berhad.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to announce that it is uplifted from being classified as an affected listed corporation effective 13 June 2022.
More info..

Malaysian Genomics Resource Centre Berhad, a leading genomics and biopharmaceutical specialist, today announced that the Group registered a 211.66% increase in revenue to RM5.08 million for the third quarter ended 31 March 2022 (3Q 2022) compared with revenue of RM1.63 million for the same quarter of the previous financial year.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical specialist, is pleased to support Yayasan Seri Negara's (YSN) Ihya Ramadhan 2022 programme through a monetary donation to help those in need.
More info..

Malaysian Genomics Resource Centre Berhad (Bursa: MGRC, 0155), a leading genomics and biopharmaceutical company, is pleased to announce the launch of its genetic screening plus personalised health supplements solutions on the airasia Super App, the region's leading travel & lifestyle digital platform.
More info..

Malaysian Genomics Resource Centre Berhad ("Malaysian Genomics" or "the Group"), a leading genomics and biopharmaceutical specialist, was recently awarded a COVID-19 surveillance contract by the Institute for Medical Research ("IMR"), the biomedical research arm of the Ministry of Health ("MOH"). Malaysian Genomics is one of the private laboratories that IMR has engaged to outsource genome surveillance of SARS-CoV2.
More info..

Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Group"), a leading genomics and biopharmaceutical specialist, is pleased to announce the entry of a new substantial shareholder, Bintai Kinden Corporation Berhad ("Bintai Kinden"), a specialist in mechanical and electrical engineering services to the construction sector, in the Group.
More info..

Malaysian Genomics Resource Centre Berhad ("MGRC" or "the Group"), a leading genomics and biopharmaceutical specialist, today announced that it recorded revenue of RM7.63 million for the second quarter ended 31 December 2021 ("2Q FY2022"), a significant increase of RM7.49 million compared with revenue of RM0.14 million for the corresponding quarter of the previous year.
More info..